Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AMAR NASDAQ:CARA NYSEAMERICAN:NTN OTCMKTS:PXSLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMARAmarillo Biosciences$0.00$0.05▼$1.97$25.24M-0.0618,253 shs6,100 shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,176 shs237,144 shsNTNNTN Buzztime$1.96-1.0%$1.19$0.94▼$7.76$5.84M0.721.63 million shs176,547 shsPXSLYPharmaxis$0.88$0.88$0.62▼$1.47$26.53M1.221,000 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMARAmarillo Biosciences0.00%0.00%0.00%0.00%0.00%CARACara Therapeutics0.00%0.00%0.00%0.00%+28.69%NTNNTN Buzztime0.00%+1.54%-19.18%+1,007.38%+3.15%PXSLYPharmaxis0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMARAmarillo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics0.2543 of 5 stars0.00.00.04.20.00.80.0NTNNTN BuzztimeN/AN/AN/AN/AN/AN/AN/AN/APXSLYPharmaxisN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMARAmarillo Biosciences 0.00N/AN/AN/ACARACara Therapeutics 0.00N/AN/AN/ANTNNTN Buzztime 0.00N/AN/AN/APXSLYPharmaxis 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMARAmarillo Biosciences$20K0.00N/AN/A($0.03) per share0.00CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00NTNNTN Buzztime$19.81M0.29$0.45 per share4.38$1.76 per share1.11PXSLYPharmaxis$8.75M3.03N/AN/A$0.04 per share22.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMARAmarillo Biosciences-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/ACARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ANTNNTN Buzztime-$2.05MN/AN/A∞N/A-61.42%-162.54%-49.94%N/APXSLYPharmaxis-$9.36MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMARAmarillo BiosciencesN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ANTNNTN BuzztimeN/AN/AN/AN/AN/APXSLYPharmaxisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMARAmarillo BiosciencesN/A0.030.07CARACara TherapeuticsN/A4.774.71NTNNTN Buzztime3.300.950.95PXSLYPharmaxis2.823.312.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMARAmarillo BiosciencesN/ACARACara Therapeutics44.66%NTNNTN Buzztime6.31%PXSLYPharmaxisN/AInsider OwnershipCompanyInsider OwnershipAMARAmarillo Biosciences34.35%CARACara Therapeutics3.10%NTNNTN Buzztime24.20%PXSLYPharmaxisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMARAmarillo Biosciences242.07 millionN/ANot OptionableCARACara Therapeutics804.57 million4.43 millionOptionableNTNNTN Buzztime192.98 millionN/ANot OptionablePXSLYPharmaxis6930.15 millionN/ANot OptionableNTN, PXSLY, AMAR, and CARA HeadlinesRecent News About These CompaniesSyntara’s Amsulostat Receives WHO INN Recognition, Boosting Myelofibrosis Treatment ProspectsJuly 7, 2025 | tipranks.comSyntara’s SNT-5505 Receives FDA Fast Track Designation for Myelofibrosis TreatmentJune 9, 2025 | tipranks.comPharmaxis Ltd Highlights Uncertainties in Syntara’s Future ProjectionsMay 6, 2025 | tipranks.comPharmaxis Ltd March Quarter Shareholder UpdateApril 30, 2025 | tipranks.comSyntara’s SNT-6302 Shows Promising Results in Scar Treatment TrialFebruary 17, 2025 | tipranks.comPharmaxis Ltd General Meeting Addresses Key ResolutionsFebruary 16, 2025 | tipranks.comPharmaxis Ltd Reveals Interim Results at Hematology ForumFebruary 3, 2025 | tipranks.comSyntara Reports Promising Interim Results for Myelofibrosis TreatmentJanuary 28, 2025 | tipranks.comPharmaxis Ltd Announces New Equity Raising InitiativeDecember 11, 2024 | tipranks.comSyntara Prepares to Unveil Promising Myelofibrosis DataDecember 9, 2024 | tipranks.comPharmaxis Ltd Director Increases Stock OptionsNovember 28, 2024 | tipranks.comPharmaxis Ltd: A Powerhouse of Pharmaceutical ExpertiseNovember 27, 2024 | tipranks.comProactive news headlines including Aurumin, PolarX, Valor Resources and Hartshead ResourcesOctober 5, 2021 | feeds.benzinga.comMedia Sentiment Over TimeNTN, PXSLY, AMAR, and CARA Company DescriptionsAmarillo Biosciences OTCMKTS:AMARAmarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.NTN Buzztime NYSEAMERICAN:NTN$1.96 -0.02 (-1.01%) As of 07/21/2025NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California.Pharmaxis OTCMKTS:PXSLY$0.88 0.00 (0.00%) As of 06/8/2021Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Block Levels Up: What S&P 500 Inclusion Means for Investors Steel Dynamics Stock Steady on Long-Term Prospects Amazon Stock Rally Hits New Highs: Buy Into Earnings? A Bullish Storm Is Brewing for High-Yield Verizon’s Share Price Forget the Hype—TSMC Is the AI Stock That Actually Delivers Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Palantir Bulls and Bears Set for an August Showdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
